Innate Pharma Sa Class A · EURONEXT:IPH
Innate Pharma Sa Class A — Investor Presentation (November 2020)
29 slides from Innate Pharma Sa Class A's investor presentation, November 2020
Slide 1: Company Overview
COMPANY OVERVIEW NOVEMBER 2020 NASDAQ: IPHA EURONEXT PARIS: IPH
Slide 2: Forward Looking Statements
Forward Looking Statements This document has been prepared by Innate Pharma S.A. (the “Company”) solely for This presentation discusses product candidates that are under clinical development the purposes of a presentation to investors concerning the Company. This document and which have not yet been
Slide 3: Investment Highlights
Investment Highlights Lacutamab: EMA PRIME and FDA Fast Track designations in R/R Sézary syndrome; Phase 2 Broad and ongoing in SS and mycosis fungoides; potential to serve as pivotal study in SS Diversified Monalizumab: First patient dosed in Phase 3 R/M SCCHN trial, triggering $50 million mile
Slide 4: Our Strategy
Our Strategy We strive to achieve scientific leadership in immunotherapy by leveraging our expertise in innate immunity and transition to a commercial stage biotech Science Commercial Finance • Deliver the current • Further shape commercial • Continue to pipeline & prepare competencies for Lumoxiti
Slide 5: Innovative Approach to Immuno-Oncology
Innovative Approach to Immuno-Oncology Three-prong approach to harness the potential of the innate immune system Immune Checkpoint Tumor Antigen Tumor Micro Inhibitor Targeting Environment Unleash Target Relieve Endogenous Immune Killing Tumor cells Immune Suppression 5
Slide 6: Three Key Strategic Pillars to Harness the Potential of the Immune System
Three Key Strategic Pillars to Harness the Potential of the Immune System Phase of Development Program Target Indication PC Ph 1 Ph 2 Ph 3 Commercial Partner Immune Checkpoint SCCHN Inhibitors (ICI) Monalizumab NKG2A Advanced Solid Tumors, Phase 1/2 including CRC Anti-Siglec-9 Siglec-9 Cancer IPH25
Slide 7: Monalizumab
MONALIZUMAB FIRST-IN-CLASS ANTI-NKG2A MAB
Slide 8: First-in-Class Anti-NKG2A mAb
Monalizumab First-in-Class Anti-NKG2A mAb Promotes anti-tumor immunity by unleashing both T & NK cells Source: André, Vivier et al., Cell 2018 8
Slide 9: Monalizumab: Lead Partnered Asset in Phase 3
Monalizumab Lead Partnered Asset in Phase 3 Phase 3 study in patients with IO pre-treated SCCHN • First patient dosed in Phase 3 study in October 2020 o Monalizumab + cetuximab in IO-pretreated R/M Phase 2 Expansion Cohort 2 squamous cell carcinoma of the head and neck (SCCHN), Monalizumab + cetuxim
Slide 10: Key Results of Cetuximab Combination: Data from Cohort 1, ESMO 2019
Monalizumab Key Results of Cetuximab Combination: Data from Cohort 1, ESMO 2019 Acceptable safety profile, ORR of 27.5% and favorable trends in OS in post IO R/M SCCHN patients Mona + Cetuximab – Best Overall Response & ORR OS in All Patients All Patients IO-naïve IO-pretreated (n=40) (n=22) (n=18)
Slide 11: Cohort 2: Preliminary Efficacy Results, Presented at ASCO20
Monalizumab Cohort 2: Preliminary Efficacy Results, Presented at ASCO20 Expansion cohort 2 confirmed prospectively the ORR reported in Cohort 1 in IO-pretreated patients Expansion Cohort 2 ASCO20 Virtual Scientific Program: Monalizumab + cetuximab • “Combination of Monalizumab and IO Pretreated R/M
Slide 12: Cetuximab Combination – Key Preliminary Results
Monalizumab Cetuximab Combination – Key Preliminary Results Antitumor Activity: Best Change of Tumor Size from Baseline Source: Cohen et al., ASCO 2020 12
Slide 13: Lacutamab
LACUTAMAB FIRST-IN-CLASS ANTIBODY TARGETING KIR3DL2
Slide 14: First-in-Class Anti-KIR3DL2 mAb
Lacutamab First-in-Class Anti-KIR3DL2 mAb • Lacutamab under development for the treatment of various forms of T-cell lymphomas (TCL) • EMA PRIME and FDA Fast Track designations for Sézary syndrome (SS) patients who have received at least two prior systemic therapies • Orphan drug designation in the
Slide 15: Lacutamab Phase I Clinical Efficacy Results
Lacutamab Phase 1 Clinical Efficacy Results Subgroup analysis All Sézary Prior treatment Sézary Syndrome Subgroup (n=35) SS without LCT 1 with syndrome (SS) N=28 mogamulizumab N=35 Best Global N=7 Response Best 42.9% 53.6% 42.9% Best change in mSWAT as compared to global (28.0 – 59.1) (35.8 – 70.5)
Slide 16: Lacutamab: Lead Late-Stage Proprietary Asset
Lacutamab Lead Late-Stage Proprietary Asset TELLOMAK Phase II Study Cohort #1: Sézary Syndrome (N~60) Mycosis Fungoides (N~90) ≥ 2 prior systemic therapies that must include ≥ 2 prior systemic therapies including biological mogamulizumab agents • Study now fully open to enrollment Cohort #2: Cohort
Slide 17: Avdoralimab, IPH5201, IPH5301
AVDORALIMAB (IPH5401) ANTI-C5AR ANTIBODY IPH5201 ANTI-CD39 ANTIBODY IPH5301 ANTI-CD73 ANTIBODY
Slide 18: Exploring Inflammation in COVID-19 and beyond
Avdoralimab Exploring Inflammation in COVID-19 and beyond COVID-19 severe pneumonia Other inflammatory diseases • Investigator-sponsored Phase 2 trial, FORCE; • Targeting C5a/C5aR has been demonstrated currently ongoing. scientifically and through positive clinical trials in • Published translationa
Slide 19: IPH5201 (Anti-CD39) and IPH5301 (Anti-CD73)
IPH5201 – IPH5301 IPH5201* (Anti-CD39) and IPH5301 (Anti-CD73) Targeting immunosuppressive tumor microenvironment • CD39 and CD73 are enzymes expressed on different cells in the TME Promote immuno-suppression by degrading pro-inflammatory ATP into immunosuppressive adenosine • IPH5201: ongoing Pha
Slide 20: IPH5201 – Preclinical Data
IPH5201 IPH5201* – Preclinical Data Significant tumor responses observed in response to treatment with PD-1 inhibitors and ADCC- inducing antibodies, as well as with immunogenic chemotherapy, compared to responses to these agents in wild-type mice Sources: Perrot Cell Reports 2019 *2018 collaboratio
Slide 21: IPH5301 – Preclinical Data
IPH5301 IPH5301 – Preclinical Data IPH5301 more potent in restoring CD4+ and CD8+ T-cell proliferation in an ATP- suppression assay, than the most advanced clinical candidates + + C D 4 T c e lls C D 8 T c e lls ( n o r m a liz e d t o c o n tr o l) * * * 1 0 0 P r o life r a tio n r a te 1 0 0 * *
Slide 22: Commercial: Lumoxiti
eres pharma COMMERCIAL LUMOXITI
Slide 23: Lumoxiti: First-in-class Marketed Product for HCL
Lumoxiti A First-in-class, Marketed Product In-Licensed from AZ for the Treatment of HCL First FDA-approved treatment for hairy cell leukemia (HCL) in over 20 years Largest trial to date (N=80) in patients with R/R HCL who First-in-class CD22-directed immunotoxin failed at least 2 prior therapies
Slide 24: Lumoxiti - marketed in the US and under regulatory review in EU
Lumoxiti Lumoxiti - marketed in the US and under regulatory review in EU Critical Success Market Opportunity 2020 Update Factors • 3L HCL patients; 380 patients in • Reaching beyond centers of • 2020 sales impacted by COVID-19 US excellence (COEs) / academic and slower adoption rate centers as patie
Slide 25: Summary
Summary Progress across our portfolio • Lacutamab granted PRIME designation by EMA 1 • Monalizumab first patient dosed in Phase 3; triggered $50 million from AstraZeneca • First patient dosed in Phase 2 IST with avdoralimab in inflammation Lumoxiti EU regulatory decision on track 2 • Completion of U
Slide 26: Key expected newsflow over next 24 months
Key expected newsflow over next 24 months Lacutamab • Prelimary effficacy data in MF (2021) • Start PTCL trials (2021) • Prelimary efficacy data in SS (2022) Monalizumab • Preliminary data on the combination of monalizumab, cetuximab and durvalumab in IO-naïve patients with R/M SCCHN (2021) Avdorali
Slide 27: Appendix
eres pharma APPENDIX
Slide 28: AstraZeneca Deals – Key Highlights
AstraZeneca Deals – Key Highlights Monalizumab IPH5201 Additional 4 Preclinical Molecules • Payments at signing, Opt-in Payment & P3 • Upfront and Ph1 FPI Payments (2018, 2020): • Upfront Payments: (2015, 2018, 2020) > USD 55m > USD20m (for all targets) > USD 400m • Near Term and Opt-in Future Payme
Slide 29: First Half 2020 Financial Highlights
First Half 2020 Financial Highlights In thousands of euros, except for data per share June 30, 2020 December 31, 2019 Revenue and other income 36,745 59,155 Research and development (31,499) (36,584) Selling, general and administrative (14,490) (9 295) Total operating expenses (45,989) (45,879) Net
Innate Pharma — Investor Presentation (November 2020) on 6ix